Ascendis Pharma A/S's (ASND) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a report issued on Monday,Benzinga reports. They presently have a $200.00 price objective on the biotechnology company's stock. Cantor Fitzgerald's target price would suggest a potential upside of 28.74% from the company's previous close.

Other research analysts have also recently issued research reports about the stock. Morgan Stanley raised shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $180.00 to $250.00 in a research report on Monday, May 5th. Royal Bank of Canada increased their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. The Goldman Sachs Group increased their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Wedbush increased their price target on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Finally, Evercore ISI increased their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $216.07.

Ascendis Pharma A/S Trading Up 2.7%

NASDAQ ASND traded up $4.10 during trading hours on Monday, reaching $155.35. The company had a trading volume of 128,101 shares, compared to its average volume of 498,969. The stock has a 50-day moving average of $156.12 and a 200 day moving average of $141.54. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $183.00. The stock has a market capitalization of $9.47 billion, a P/E ratio of -21.82 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. As a group, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

Institutional investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $28,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $30,000. Jones Financial Companies Lllp lifted its position in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after buying an additional 197 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after buying an additional 328 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $96,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.